Skip to main content

March 2018, Vol 11, Ninth Annual Payers' Guide

Payers' Guide, FDA Approvals
Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Lisa A. Raedler, PhD, RPh
Read More
Page 4 of 4
Results 31 - 31 of 31